Cigarette Smoke Nasal and Whole Blood Challenge in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Lung Diseases, Obstructive
About this trial
This is an interventional diagnostic trial for Lung Diseases, Obstructive focused on measuring cigarette smoke, nasal, whole blood, cytokines, chemokines, nasal fluid, filter paper
Eligibility Criteria
Inclusion Criteria (COPD Smokers): Smokers currently on at least 5 cigarettes per day, with a history of >10 pack years Post-bronchodilator FEV1 >30% of predicted and < 80% of predicted Pre-bronchodilator FEV1/FVC of <70% With or without chronic simple bronchitis Exclusion criteria (COPD Smokers): History of asthma, allergy (including rhinitis/eczema) Reversibility : an increase in FEV1 that is >400ml from the baseline pre- bronchodilator value (bronchodilate with salbutamol 400g delivered from a metered dose inhaler (MDI) into a spacer). Inclusion criteria (for "Healthy" Smokers): Smokers currently on at least 5 cigarettes per day, with a history of >10 pack years FEV1 >90% of predicted, FEV1/FVC of >70% Cannot have chronic simple bronchitis Age, sex, smoking history matched to COPD Smokers Exclusion criteria (for "Healthy" Smokers): History of asthma, allergy (including rhinitis/eczema Reversibility: an increase in FEV1 that is both >400ml from the baseline pre-bronchodilator value (bronchodilate with salbutamol 400mcg delivered from a metered dose inhaler (MDI) into a spacer)P Pregnancy
Sites / Locations
- National Heart & Lung Institue Clinical Studies Unit, Imperial College London